Diabetic Nephropathy News | Diabetes & Renal Research Studies

Diabetic Nephropathy


Canagliflozin Trial for T2D, CKD Halted Due to Positive Results

A clinical trial assessing canagliflozin (Invokana; Janssen) as an addition to standard-of-care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been stopped early after meeting its pre-specified efficacy criteria.
Next post in Chronic Kidney Disease (CKD)